European Journal of Clinical Pharmacology

, Volume 35, Issue 1, pp 21–24 | Cite as

Doxazosin in patients with hypertension

  • K. A. Conrad
  • T. C. Fagan
  • M. J. Mackie
  • P. V. Mayshar
  • S. Lee
  • J. F. Souhrada
  • F. C. Falkner
  • J. D. Lazar
Originals

Summary

The antihypertensive effects and steady-state pharmacokinetics of doxazosin, as well as the bioequivalence of four dosage forms, were studied in 25 hypertensive patients.

For an 8 mg daily dose mean Cmax at steady-state for all patients was 108 ng/ml; the mean tmax was 1.8 h. The mean terminal elimination half-life was 22 h. The four tablets containing 1, 2, 4, or 8 mg of doxazosin were bioequivalent in delivering the 8 mg dose.

In patients with mild to moderate hypertension, 26-day treatment with doxazosin resulted in blood pressure reduction of 10/7 mm Hg in the supine and 13/18 mm Hg in the standing position. Adverse effects were generally mild and of brief duration.

Key words

doxazosin hypertension alpha-adrenergic blockade bioavailability pharmacokinetics adverse effects 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Cubeddu LX, Fuenmayor N, Caplan N, Ferry D (1987) Clinical pharmacology of doxazosin in patients with essential hypertension. Clin Pharmacol Ther 41: 439–449Google Scholar
  2. 2.
    Elliot HL, Meredith PA, Sumner DJ, McLean K, Reid JL (1982) A pharmacodynamic and pharmacokinetic assessment of a new α-adrenoceptor antagonist, doxazosin (UK 33274) in normotensive subjects. Br J Clin Pharmacol 13: 699–703Google Scholar
  3. 3.
    Vincent J, Elliot HL, Meredith PA, Reid JL (1983) Doxazosin, an α-adrenoceptor antagonist: Pharmacokinetics and concentration-effect relationships in man. Br J Clin Pharmacol 15: 719–725Google Scholar

Copyright information

© Springer-Verlag 1988

Authors and Affiliations

  • K. A. Conrad
    • 1
  • T. C. Fagan
    • 1
  • M. J. Mackie
    • 1
  • P. V. Mayshar
    • 1
  • S. Lee
    • 1
  • J. F. Souhrada
    • 2
  • F. C. Falkner
    • 2
  • J. D. Lazar
    • 2
  1. 1.University of Arizona College of MedicineTucson
  2. 2.Pfizer Central Research Groton

Personalised recommendations